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Abbreviations
AcLDL  Acetylated low density lipoprotein
HMDM  Human monocyte-derived macrophages
LDL  Low density lipoprotein
LPL  Lipoprotein lipase
LY  Lucifer Yellow
PI3K  Phosphoinositide 3-kinase
RT-qPCR  Real-time quantitative PCR
SR-A  Scavenger receptor-A
Introduction
Atherosclerosis, the underlying cause of myocardial 
infarction and stroke, is responsible for most deaths in 
western society [1]. The disease is initiated by the acti-
vation of the arterial endothelium by various risk factors, 
such as LDL cholesterol and hypertension, which results 
in the secretion of chemokines, such as monocyte chemo-
tactic protein-1, by endothelial cells [1, 2]. These attract 
immune cells, particularly T-lymphocytes and monocytes, 
in a process that is aided by increased expression of adhe-
sion molecules on the endothelial cell surface [1, 2]. The 
recruited monocytes differentiate into macrophages, which 
can then take up modified lipoproteins to form lipid-laden 
foam cells [1, 2]. As the disease progresses, complex 
fibrotic plaques are formed due to the combined action 
of foam cell lysis, defective efferocytosis, migration and 
proliferation of smooth muscle cells from the media to the 
intima, and synthesis of extracellular matrix by them [1, 
2]. Rupture of such plaques by proteolytic enzymes pro-
duced by macrophages as part of a continued inflammatory 
Abstract The transformation of macrophages into lipid-
loaded foam cells is a critical early event in the pathogen-
esis of atherosclerosis. Both receptor-mediated uptake of 
modified LDL, mediated primarily by scavenger receptors-
A (SR-A) and CD36 along with other proteins such as lipo-
protein lipase (LPL), and macropinocytosis contribute to 
macrophage foam cell formation. The signaling pathways 
that are involved in the control of foam cell formation are 
not fully understood. In this study, we have investigated 
the role of phosphoinositide 3-kinase (PI3K) in relation to 
foam cell formation in human macrophages. The pan PI3K 
inhibitor LY294002 attenuated the uptake of modified LDL 
and macropinocytosis, as measured by Lucifer Yellow 
uptake, by human macrophages. In addition, the expression 
of SR-A, CD36 and LPL was attenuated by LY294002. 
The use of isoform-selective PI3K inhibitors showed that 
PI3K-β, -γ and -δ were all required for the expression of 
SR-A and CD36 whereas only PI3K-γ was necessary in the 
case of LPL. These studies reveal a pivotal role of PI3K in 
the control of macrophage foam cell formation and provide 
further evidence for their potential as therapeutic target 
against atherosclerosis.
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response leads to thrombosis and subsequent clinical com-
plications of this disease [1, 2].
The transformation of macrophages into foam cells is a 
critical early event in the pathogenesis of atherosclerosis 
[1, 2]. The uptake of modified LDL by a receptor-mediated 
mechanism via increased expression of key genes, such 
as scavenger receptor-A (SR-A) and CD36, by the invad-
ing macrophages represents a major mechanism [1, 2]. In 
addition, the lipoprotein lipase (LPL) expressed by mac-
rophages contributes to foam cell formation via a so-called 
“bridging action” that leads to the accumulation of modi-
fied lipoproteins at the cell surface and their subsequent 
uptake by the cells [3, 4]. Receptor-independent mecha-
nisms, particularly macropinocytosis, also play an impor-
tant role in foam cell formation [5, 6]. Macropinocytosis 
is a form of fluid-phase endocytosis where the uptake of 
solute does not reach saturation when its concentration is 
increased (i.e. solute uptake is directly proportional to its 
concentration) [5, 6]. The process involves actin-dependent 
ruffling of the plasma membrane and the subsequent fusion 
of the membrane to itself to form intracellular fluid filled 
vacuoles 0.5–5 µM in diameter [5, 6]. Although an impor-
tant role for macropinocytosis in the uptake of native LDL 
is well established [5, 6], our recent studies have extended 
the role of this process to the uptake of modified LDL 
by macrophages [7, 8]. Previous studies have shown that 
PI3K plays a potentially important role in macropinocy-
tosis, including the uptake of native LDL, under certain 
conditions [5, 6]. However, the role of PI3K in the uptake 
of modified LDL and the expression of key genes impli-
cated in this process is not fully understood, and formed the 
focus of the current study.
Materials and Methods
Reagents
LY294002 was obtained from Merck Millipore (Cal-
biochem) whereas isoform-specific inhibitors TGX-221, 
IC-87114 and AS-605240 were from Selleck Chemicals. 
1,1′-Dioctadecyl-3,3,3′,3′-tetramethyllindocarbocyane 
perchlorate (DiI)-labeled acetylated LDL (DiI-AcLDL) 
was purchased from Intracel. All the other chemicals were 
obtained from Sigma-Aldrich unless otherwise stated.
Cell Culture
Human monocyte-derived macrophages (HMDM) were dif-
ferentiated from monocytes isolated from buffy coats from 
the Welsh Blood Service using Ficoll-Hypaque purification 
as previously described [7–10]. The human monocytic leu-
kemia THP-1 cell line and HMDM were grown in RPMI-
1640 supplemented with 10 % (v/v) heat-inactivated fetal calf 
serum, penicillin (100 U/ml), streptomycin (100 µg/ml) and 
L-glutamine (2 mmol/l) (Invitrogen) at 37 °C in a humidified 
atmosphere containing 5 % (v/v) CO2. The THP-1 monocytes 
were differentiated into macrophages using 160 nM of PMA 
for 24 h, a period corresponding to high levels of expression 
of scavenger receptors and other key genes implicated in the 
regulation of macrophage foam cell formation [7–12].
DiI-AcLDL and Lucifer Yellow Uptake Assays
THP-1 macrophages were treated for 24 h at 37 °C with 
10 µg/ml DiI-AcLDL or 100 µg/ml Lucifer Yellow (LY) 
(concentrations of both based on previous studies) in 
RPMI-1640 containing 0.2 % (v/v) fatty-acid free BSA 
[8–10]. The uptake was analyzed by flow cytometry on a 
FACS Canto (BD Biosciences, Oxford, UK) flow cytom-
eter with 10,000 events acquired for each sample. The 
uptake was represented as a percentage with the vehicle-
treated control arbitrarily assigned as 100 %.
Real-Time Quantitative PCR
The extraction of RNA, reverse transcription and real-time 
quantitative PCR (RT-qPCR) of the genes analyzed was 
carried out as previously described [7–10]. The sequences 
of the primers were: 5′-CCAGGGACATGGAATGCAA-3′ 
and 5′-CCAGTGGGACCTCGATCTCC-3′ for SR-A [13]; 
5′-GAGAACTGTTATGGGGCTAT-3′ and 5′-TTCAACT 
GGAGAGGCAAAGG-3′ for CD36 [13]; 5′-GAGATTTCT 
CTGTATGGCACC-3′ and 5′-CTGCAAATGAGACACTT 
TCTC-3′ for LPL [14]; and 5′-CCTGGAGGAGAAGAG 
GAAAGAGA-3′ and 5′-TTGAGGACCTCTGTGTATTTG 
TCAA-3′ for 60S ribosomal protein L13a (RPL13A). 
The fold changes in expression were determined using 
2−
(
Ct1−Ct2
)
, where ∆Ct represents the difference 
between the threshold cycle (Ct) for each target gene and 
RPL13A mRNA transcript levels.
Western Blot Analysis
Total cell lysates were size-fractionated on SDS-poly-
acrylamide gels (Life Technologies) and then analyzed by 
Western blot analysis as previously described [7, 9, 10]. 
Antibodies were either from Santacruz Biotechnology 
[SR-A (sc-20660), CD36 (sc-9154)] or Sigma-Aldrich 
(β-actin). Semi-quantitative measurement of signals in 
Western blots was performed by densitometric analysis 
using the Image J software.
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Statistical Analysis
The Student’s t test was used for single comparisons. For 
multiple comparisons, one-way ANOVA with Tukey’s or 
Games-Howell post hoc analysis was used. Values of P 
were considered significant below 0.05.
Results
The Uptake of Modified LDL by Human Macrophages  
is Attenuated by the PI3K Inhibitor LY294002
PMA differentiated THP-1 macrophages are widely used 
as a model system to investigate the regulation of mac-
rophage function and gene expression in relation to ath-
erosclerosis with demonstrated conservation of responses 
to primary cultures and in vivo [7–12, 14]. This model 
system was used initially to investigate the uptake of 
AcLDL, which is widely used for such assays because 
the cells avidly take them up and shows excellent correla-
tion with the uptake of oxidized LDL [7–10, 15, 16]. The 
effect of the pan PI3K inhibitor, LY294002, on AcLDL 
uptake by THP-1 macrophages was first investigated. As 
shown in Fig. 1, the inhibitor produced a statistically sig-
nificant inhibition of AcLDL uptake of about 60 %. The 
concentration of LY294002 used in these initial experi-
ments was 100 µM and hence it was decided to carry out 
a dose response experiment. The reduction in AcLDL 
uptake was observed with 10 µM LY294002 with maxi-
mal decrease at the 100 µM concentration (Supplemen-
tary Figure 1).
In order to rule out the possibility that the inhibition of 
AcLDL uptake by LY294002 was peculiar to the THP-1 
cell line, representative experiments were carried out on 
primary cultures of HMDM. As shown in Fig. 2, LY294002 
also inhibited the uptake of AcLDL by HMDM by approxi-
mately 60 %. Thus, LY294002 inhibits AcLDL uptake in 
both THP-1 macrophages and HMDM.
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Fig. 1  LY294002 attenuates AcLDL uptake by THP-1 macrophages. 
The uptake of DiI-AcLDL was determined in response to 24 h of 
incubation with DMSO vehicle control or 100 µM LY294002. 
Data represent means ± SD from four independent experiments, 
the uptake in vehicle treated cells has been arbitrarily assigned as 
100 %. Statistical analysis was performed using the Student’s t test, 
***P < 0.001
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Fig. 2  LY294002 attenuates AcLDL uptake by HMDM. The uptake 
of DiI-AcLDL was determined in response to 24 h incubation with 
DMSO vehicle control or 100 µM LY294002. Data represent 
means ± SD from three independent experiments, the uptake in vehi-
cle treated cells has been arbitrarily assigned as 100 %. Statistical 
analysis was performed using the Student’s t test, ***P < 0.001
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Fig. 3  LY294002 inhibits LY uptake in human macrophages. LY 
uptake was determined in THP-1 macrophages (a) or HMDM (b) in 
response to 24 h incubation with DMSO vehicle control or the indi-
cated concentration of LY294002. Data represent means ± SD from 
three independent experiments, the uptake in vehicle treated cells has 
been arbitrarily assigned as 100 %. Statistical analysis was performed 
using one-way ANOVA with Games-Howell (a) or Tukey’s (b) post 
hoc analysis, ***P < 0.001, **P < 0.01
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LY294002 Inhibits LY Uptake and Macropinocytosis 
by Human Macrophages
The fluorescent dye LY is commonly used to monitor macro-
pinocytosis [7, 8, 17]. The action of LY294002 on LY uptake 
was investigated in THP-1 macrophages and HMDM. Fig-
ure 3a shows that LY294002 inhibits the uptake of LY at all 
the concentrations used (10, 50 and 100 µM). In the case of 
HMDM, LY294002 had no effect on LY uptake at 10 µM but 
produced a significant reduction at 50 and 100 µM (Fig. 3b). 
Thus, a similar trend in the action of LY294002 on the uptake 
of LY was observed in both THP-1 macrophages and HMDM.
LY294002 Inhibits the Expression of SR-A, CD36 
and LPL in Human Macrophages
The effect of LY294002 on the expression of key genes in 
macrophages implicated in the uptake of modified LDL 
Fig. 4  LY294002 inhibits the expression of SR-A, CD36 and LPL 
mRNA in THP-1 macrophages. THP-1 macrophages were incu-
bated for 24 h with the DMSO vehicle or 10 µM LY294002 (empty 
bars) or 100 µM LY294002 (filled bars). Total RNA was subjected 
to real-time quantitative PCR using primers against SR-A, CD36 or 
LPL as indicated. The mRNA expression levels were calculated using 
the comparative Ct method and normalized to RPL13A with vehicle-
treated cells given an arbitrary value of 1. Data represent means ± SD 
from three (for 100 µM LY294002) or five (for 10 µM LY294002) 
independent experiments. Statistical analysis was performed using 
the Student’s t test, ***P < 0.001
Fig. 5  The effect of LY294002 on the expression of SR-A, CD36 
and LPL mRNA in HMDM. HMDM were incubated for 24 h with 
the DMSO vehicle or 10 µM LY294002 (empty bars) or 100 µM 
LY294002 (filled bars). Total RNA was subjected to real-time quan-
titative PCR using primers against SR-A, CD36 or LPL as indicated. 
The mRNA expression levels were calculated using the compara-
tive Ct method and normalized to RPL13A with vehicle-treated cells 
given an arbitrary value of 1. Data represent means ± SD from three 
independent experiments. Statistical analysis was performed using 
the Student’s t test, ***P < 0.001
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was next investigated. LY294002 was used at two differ-
ent concentrations, 10 and 100 µM. As shown in Fig. 4, 
LY294002 at both concentrations attenuated the expression 
of SR-A, CD36 and LPL mRNA in THP-1 macrophages. 
In the case of HMDM, LY294002 inhibited the mRNA 
expression of all three genes when used at a concentra-
tion of 100 µM though a significant reduction of only 
SR-A mRNA levels was observed with 10 µM LY294002 
(Fig. 5). Thus, a similar trend of action of LY294002 was 
observed in both THP-1 macrophages and HMDM.
In order the investigate whether the effect of LY294002 
on mRNA expression was also accompanied by corre-
sponding changes in protein levels, Western blot analysis 
was carried out on SR-A and CD36 in THP-1 macrophages. 
As shown in Fig. 6, a significant reduction in the steady 
state levels of SR-A and CD36 was observed with 100 µM 
LY294002. Thus, LY294002 decreased both mRNA and 
protein expression of SR-A and CD36.
In the case of RT-qPCR and Western blot analysis, the 
expression of genes implicated in the uptake of modified LDL 
(i.e. SR-A, CD36 or LPL) were normalized to a housekeep-
ing gene (RPL13A for RT-qPCR and β-actin for Western blot 
analysis). These findings suggest that the marked reduction in 
gene expression is unlikely because of an effect of LY294002 
on cell viability. Nevertheless, representative experiments on 
cell viability were carried out using the crystal violet assay. 
As shown in Supplementary Figure 2, LY294002 had no 
significant effect on the viability of HMDM at all concentra-
tions used. A slight but significant reduction in the viability 
of THP-1 macrophages was observed with 50 and 100 µM 
LY294002. Overall, these results confirm that the marked 
action of LY294002 on gene expression cannot be attributed to 
changes in cell viability as inhibition of gene expression was 
observed at concentrations that has no effect on cell viability 
(i.e. all concentrations in HMDM and 10 µM in THP-1 cells). 
In addition, the extent of changes in gene expression at 50 and 
100 µM LY294002 in THP-1 macrophages was substantially 
greater than that observed at the level of cell viability.
More Isoform-Selective Inhibitors of the PI3K Pathway 
also Attenuate the Expression of SR-A, CD36 and LPL 
in Human Macrophages
In order to further evaluate the importance of PI3K signaling, 
the action of three isoform-specific inhibitors, TGX-221 (β), 
IC-87114 (δ) and AS-605240 (γ), on the expression of SR-A, 
CD36 and LPL mRNA was next investigated. Preliminary 
dose response experiments using LY294002 as a positive 
control showed that maximal inhibition, where obtained, was 
achieved at 10 µM concentration (Supplementary Figure 3) 
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Fig. 6  LY294002 inhibits the steady state levels of SR-A and CD36 
in THP-1 macrophages. THP-1 macrophages were incubated for 24 h 
with the DMSO vehicle or 10 or 100 µM LY294002. Equal amount 
of protein extracts were subjected to Western blot analysis using 
antisera against SR-A, CD36 or β-actin. The image shown is repre-
sentative of three independent experiments. The histograms show 
the levels of SR-A or CD36 normalized to β-actin (means ± SD), as 
determined by densitometric analysis, with the relative expression 
in DMSO control arbitrarily assigned as 1. Statistical analysis was 
performed using one-way ANOVA with Tukey’s post hoc analysis, 
*P < 0.05, **P < 0.01
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so this concentration was used for subsequent studies. The 
expression of SR-A and CD36 was significantly attenuated 
by all three inhibitors, thereby suggesting the role of mul-
tiple PI3K isoforms in the regulation (Fig. 7). On the other 
hand, a significant reduction of LPL was only obtained with 
the PI3Kγ-specific inhibitor AS-605240 (Fig. 7).
Discussion
Macrophage foam cell formation is a complex process with 
receptor-mediated uptake of modified LDL along with 
other processes such as macropinocytosis playing key roles 
[1, 2, 5, 6]. The impact of different signaling pathways on 
macrophage uptake of modified LDL along with associated 
changes in gene expression is so far poorly understood. 
We show here that the PI3K signaling pathway is critical 
for the uptake of modified LDL, macropinocytosis and the 
expression of key genes implicated in this process.
Receptor-mediated endocytosis plays a key role in 
the uptake of modified LDL with SR-A and CD36 being 
important regulators of the process [1, 2]. For example, 
CD36-dependent signaling cascade was demonstrated to 
be critical for macrophage foam cell formation [18] and 
deficiency of SR-A or CD36 was found to reduce athero-
sclerotic development in mouse model systems [19, 20]. 
However, not all studies have indicated such a key role at 
least as far as foam cell formation is concerned [21, 22]. 
This suggests that either other genes and/or non-receptor-
mediated processes contribute to macrophage foam cell 
formation. The LPL enzyme expressed by macrophages 
has been shown to contribute to foam cell formation 
because of its ability to bind to both the cell surface and 
lipoproteins via different regions that cause the accumula-
tion of the latter and their subsequent uptake by the cells 
(bridging action) [3, 4]. Interestingly, our previous stud-
ies had shown that PI3K is involved, at least in part, in 
the IFN-γ-mediated regulation of LPL expression [23] 
and this study extends this to its constitutive expression 
in human macrophages. In addition to receptor-mediated 
uptake of LDL, fluid-phase pinocytosis, particularly 
macropinocytosis, has recently been found to play an 
important role in the control of macrophage foam cell 
formation [5, 6]. Previous studies on the importance of 
macropinocytosis were restricted to LDL [5, 6, 24, 25] 
but we found that this also extends to modified LDL [7]. 
Overall, our studies demonstrate that PI3K is important 
for both receptor-mediated uptake processes and macropi-
nocytosis, and confirms links that were identified in some 
previous studies [5, 6, 24–26].
The PI3K family is complex with at least three distinct 
classes, some with several members, and inhibitors against 
the catalytic subunits of Class Ia family (p110α, p110β and 
p110δ) are being developed as therapeutic agents against 
several aspects of cardiovascular disease [27–29]. In terms 
of studies on mouse model systems, previous research 
has been restricted to PI3Kγ whose deletion was found to 
attenuate the development of atherosclerosis [30, 31]. Inter-
estingly, PI3Kγ was also found to be critical for granulo-
cyte macrophage-colony stimulating factor-differentiated 
murine macrophages to become foam cells by fluid-phase 
pinocytosis of LDL [24]. In contrast, fluid-phase pinocyto-
sis of native LDL by macrophage colony stimulating fac-
tor-differentiated macrophages was not affected by phar-
macological inhibition of all four-class I PI3K isoforms 
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Fig. 7  The effect of isoform-specific PI3K inhibitors on the expres-
sion of SR-A, CD36 and LPL. THP-1 macrophages were incubated 
for 24 h with the DMSO vehicle or 10 µM of TGX-221, IC-87114 or 
AS-605240. Total RNA was subjected to real-time quantitative PCR 
using primers against a SR-A, b CD36 or c LPL as indicated. The 
mRNA expression levels were calculated using the comparative Ct 
method and normalized to RPL13A with vehicle-treated cells given 
an arbitrary value of 1. Data represent the means ± SD from four 
independent experiments. Statistical analysis was performed using 
one-way ANOVA with Games-Howell post hoc analysis, *P < 0.05, 
**P < 0.01, ***P < 0.001
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[25]. This suggests that the overall role of PI3K family in 
the control of macrophage foam cell formation is likely 
to be complex. Interestingly, our studies also show that 
whereas specific inhibitors against PI3K-β, -γ and -δ all 
inhibit the expression of SR-A and CD36, LPL levels are 
only affected by the PI3Kγ inhibitor (Fig. 7). These data 
argue against inhibition of a single isoform in the therapeu-
tic intervention of macrophage foam cell formation.
In conclusion, we have demonstrated a pivotal role of 
PI3K signaling in the uptake of modified LDL, macropi-
nocytosis and the expression of key genes implicated in 
the control of foam cell formation in human macrophages. 
Future studies should investigate the molecular mecha-
nisms underlying PI3K actions leading to changes in the 
expression of key genes implicated in foam cell formation.
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